Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Novel mechanism to turn on cancer-killing T cells identified

Novel mechanism to turn on cancer-killing T cells identified

COVID-19 vaccine effectiveness wanes more quickly in cancer patients, study finds

COVID-19 vaccine effectiveness wanes more quickly in cancer patients, study finds

Penn Medicine and CHOP announce plans with Costa Rica's CCSS for CAR T research

Penn Medicine and CHOP announce plans with Costa Rica's CCSS for CAR T research

NCCN announces the recipients of 2022 awards for oncology champions advancing cancer care

NCCN announces the recipients of 2022 awards for oncology champions advancing cancer care

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

Adolescent and young adult leukemia survivors have reduced long-term survival compared to peers without cancer

Adolescent and young adult leukemia survivors have reduced long-term survival compared to peers without cancer

Unique binding property may explain the ability of delta variant to spread more rapidly

Unique binding property may explain the ability of delta variant to spread more rapidly

New classification by ESMO to guide research on treatment de-escalation in oncology

New classification by ESMO to guide research on treatment de-escalation in oncology

Decoy ACE2 nanoparticles block the entry of SARS-CoV-2 into cells

Decoy ACE2 nanoparticles block the entry of SARS-CoV-2 into cells

Targeting the mitochondrial pathway may be a potential strategy to halt prostate cancer growth

Targeting the mitochondrial pathway may be a potential strategy to halt prostate cancer growth

Researchers make breakthrough in overcoming drug resistance in a rare, devastating blood cancer

Researchers make breakthrough in overcoming drug resistance in a rare, devastating blood cancer

The Josep Carreras Leukaemia Research Institute joins Cancer Proteome Project

The Josep Carreras Leukaemia Research Institute joins Cancer Proteome Project

Novel method could bring life-saving benefits of CAR T-cell therapy to patients with acute myeloid leukemia

Novel method could bring life-saving benefits of CAR T-cell therapy to patients with acute myeloid leukemia

Novel plug-and-play multi-organ chip can be customized to the patient

Novel plug-and-play multi-organ chip can be customized to the patient

CRISPR/Cas9 deletions induce adverse on-target genomic effects

CRISPR/Cas9 deletions induce adverse on-target genomic effects

Study determines how much U.S. hospitals mark up the price of cancer therapies

Study determines how much U.S. hospitals mark up the price of cancer therapies

Scientists identify innovative treatment approach for arterial thromboses

Scientists identify innovative treatment approach for arterial thromboses

CAR T-Cell Therapy: The Future of Cancer and HIV Treatment?

CAR T-Cell Therapy: The Future of Cancer and HIV Treatment?

Scientists identify a way to reverse drug resistance by rewiring the inner workings of leukemia cells

Scientists identify a way to reverse drug resistance by rewiring the inner workings of leukemia cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.